Gelonghui, September 14 | Huayuan Securities Research Report indicates that HiCisco (002653.SZ) cyclopofol is growing rapidly, the pipeline of innovative drugs continues to be rich, and the first half of the year's results are in line with market expectations. Innovative drugs are being released rapidly, and the generic drug sector is stabilizing. As of 24H1, cyclopofol has covered more than 2,500 hospitals. According to medical Rubik's cube magnified data, as of May 2024, the market share of cyclopofol in intravenous anesthesia has reached 21.51%, surpassing similar products such as propofol, imidazole, dextromide, and rema for two consecutive months. Furthermore, innovative drugs continue to be rich in research pipelines, and long-term steady growth can be expected. Hengrui Pharmaceutical, Xinlitai, and Colon Pharmaceutical were selected as comparable companies. Considering that cyclopophenol is growing rapidly and there is a large future market space, new drugs under development are continuously enriched and covered for the first time, giving them a “buy” rating.